Skip to main content

GalNAc-L96 - A Key Molecule for Efficient RNA Targeted Delivery

Introduction to GalNAc-L96

GalNAc-L96 (CAS 1159408-62-4) is a triantennary N-acetylgalactosamine (GalNAc) ligand primarily used for the synthesis of GalNAc-siRNA. GalNAc is a specific ligand for ASGPR (Asialoglycoprotein Receptor), enabling liver-targeted delivery, which is a crucial aspect of modern RNA delivery technology.

Applications and Advantages of GalNAc-L96

  1. Precise Liver-Targeted Delivery: ASGPR is highly expressed on liver cell surfaces, allowing siRNA, antisense oligonucleotides (ASO), or other nucleic acid drugs conjugated with GalNAc-L96 to efficiently enter liver cells and enhance therapeutic effects.
  2. Enhanced Bioavailability of siRNA: Traditional siRNA delivery methods (such as lipid nanoparticles, LNPs) often lead to non-specific distribution, whereas GalNAc-conjugated siRNA (GalNAc-siRNA) enables more efficient and safer RNA interference (RNAi) therapy.
  3. Reduced Systemic Toxicity: Due to the high specificity of GalNAc delivery, compared to LNPs, GalNAc-siRNA exhibits lower immunogenicity and reduced side effects, making it a preferred strategy for RNA drug development.
  4. Improved Stability and Optimized Pharmacokinetics: By optimizing the structure of GalNAc-L96, its affinity for ASGPR can be enhanced, thereby increasing hepatic cell uptake and prolonging in vivo half-life.

Watson’s Unique Advantages in the GalNAc Field

  1. Advanced Synthesis Techniques and Purity Control
  • Watson leverages cutting-edge glycochemistry and nucleic acid modification technologies to provide high-purity, high-quality GalNAc-L96 and its derivatives, ensuring optimal outcomes in RNAi and ASO drug development.
  1. Comprehensive Support from Lab to Industrial Scale
  • Watson not only supplies small-scale research-grade products but also has pilot and industrial-scale production capabilities, meeting the demands from early-stage research to clinical production.
  • Strict adherence to quality management systems (ISO certification) ensures product quality and stability.
  1. Strong Technical Expertise and Industry Recognition
  • With years of experience in glycoconjugates and RNA delivery, Watson collaborates with leading pharmaceutical and biotechnology companies worldwide, driving advancements in RNA therapeutics.
  • Watson’s high-end customization and innovative synthesis capabilities make it a key global partner in RNA delivery technologies.

Conclusion

As a core ligand for RNA-targeted delivery, GalNAc-L96 plays a vital role in siRNA and ASO therapies. With cutting-edge synthesis technologies, strict quality control, and strong customization capabilities, Watson holds a distinct competitive advantage in this field, supporting breakthroughs in RNA delivery technology.

If you are interested in GalNAc-related products or RNA delivery solutions, feel free to contact Watson for more information!

Reference

GalNAc-L96 on Watson International

Comments

Popular posts from this blog

Watson's PDHP CAS 34562-31-7 The Secret to Light Yellow Liquid Appearance

In the competitive world of chemical manufacturing, maintaining consistency and meeting precise specifications are essential for success. One compound that highlights these principles is 3,5-Diethyl-1,2-dihydro-1-phenyl-2-propylpyridine, commonly known as PDHP, with the CAS number 34562-31-7. PDHP is a versatile compound utilized in various industrial applications, including rubber additives and catalytic processes. Among its many attributes, Watson’s ability to consistently produce PDHP as a light yellow liquid stands out, especially in industries where the appearance of the final product is crucial. PDHP serves a vital role in several industrial sectors. In the rubber industry, it functions as an additive that enhances the durability and longevity of rubber products. PDHP’s properties help improve the stability of rubber, making it more resistant to environmental wear and tear. Additionally, in catalysis, PDHP’s structure allows it to act as an effective ligand or catalyst precurso...
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data Identification Product Namemethylammonium iodideIUPAC Namemethylazanium;iodide Molecular StructureCAS Registry Number 14965-49-2MDL NumberMFCD28100833SynonymsMethylammonium iodide14965-49-2methylazanium;iodideEINECS 239-037-4methylazanium iodideMethanamine, hydriodideMethyl ammonium iodideMethylamine.hydriodicacidSCHEMBL1534750Methylammonium Iodide, anhydrousDB-221235NS00086090Molecular FormulaCH6INMolecular Weight158.97InChIInChI=1S/CH5N.HI/c1-2;/h2H2,1H3;1HInChI KeyLLWRXQXPJMPHLR-UHFFFAOYSA-N  Canonical SMILESC. Patent InformationPatent IDTitlePublication DateWO2023/180219A METHOD FOR SYNTHESIS OF HALIDE SALTS2023CN113845428Preparation method of perovskite material powder2021WO2018/169373METHOD OF PREPARING LUMINESCENT NANO-SHEET, LUMINESCENT NANO-SHEET MATERIAL, LUMINESCENT NANO-SHEET FILM, BACK LIGHT, AND LIQUID CRYSTAL DISPLAY APPARATUS2018WO2015/32748AMORPHOUS MATERIAL AND THE USE THEREOF2018 ...
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data Identification Product NameNickel HydroxideIUPAC Namenickel;dihydrate Molecular StructureCAS Registry Number 12054-48-7EINECS Number235-008-5MDL NumberMFCD00011140Beilstein Registry NumberSynonyms12054-48-7AKOS015903693CS-0089243dihydroxynickelEC 235-008-5EINECS 235-008-5HSDB 1827LS-96321MFCD00011140Nickel dihydroxideNickel hydroxide (II)Nickel hydroxide (Ni(OH)2)Nickel hydroxide (ous)Nickel Hydroxide nanowireNickel(2+) hydroxidenickel(II) dihydroxideNickel(II) hydroxide, for analysisnickel;dihydrateNickelous hydroxideUNII-L8UW92NW6JMolecular FormulaH4NiO2Molecular Weight94.724 InChIInChI=1S/Ni.2H2O/h;2*1H2 InChI KeyAIBQNUOBCRIENU-UHFFFAOYSA-N  Canonical SMILESO.O.   Physical Data AppearanceGreen powder Spectra Description (IR Spectroscopy)Solvent (IR Spectroscopy)Temperature (IR Spectroscopy), °CBandssolid matrix-258 Description (UV/VIS Spectroscopy)Solvent (UV/VIS Spectroscopy)Comment (UV/VIS Spec...